Skip to content
ChickenStockChickenStock
ResearchXENE
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals (XENE) stock

NASDAQ

$40.48-1.26%(-0.52)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-9.27x

Net loss — not comparable

P/B

3.46x

P/S

495.88x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

7 SEC filings
  • Kelly Thomas PatrickChief Financial Officer · Oct 15, 2026Option exercise7,500 shares
    22,500 shares held after
  • MORTIMER IANPRESIDENT & CEO · Sep 30, 2026Open-market purchase30,000 shares · $1.1M
    Avg. price $37.3849,923 shares held after
  • Kelly Thomas PatrickChief Financial Officer · Sep 30, 2026Open-market purchase15,000 shares · $560K
    Avg. price $37.31615,000 shares held after
  • Svoronos DawnDirector · Sep 1, 2026Option exercise5,144 shares · $42K
    Avg. price $8.1531,373 shares held after
  • KENNEY CHRISTOPHER JOHNChief Medical Officer · Aug 28, 2026Open-market sale7,068 shares · $426K
    Avg. price $60.2475
    Show 2 price lots
    • 6,368 shares × $60.1673$383K
    • 700 shares × $60.9766$43K
  • GANNON STEVENDirector · Aug 11, 2026Open-market sale10,000 shares · $641K
    Avg. price $64.0551,870 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Xenon Pharmaceuticals (XENE) stock information

NASDAQ

Xenon Pharmaceuticals (XENE) is listed on NASDAQ. Its market capitalization is about $4B. On trailing-twelve-month earnings the P/E ratio is -9.27, and the P/B ratio is 3.46. Return on equity is -37.3%. These figures are computed in-house from official filings and are reference information only.

Xenon Pharmaceuticals — frequently asked questions

What is the P/E ratio of Xenon Pharmaceuticals (XENE)?
On a trailing-twelve-month basis, XENE trades at a P/E ratio of -9.27. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Xenon Pharmaceuticals?
XENE has a market capitalization of about $4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.